Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo

  title={Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo},
  author={David Boczkowski and Smita K. Nair and David J. Snyder and Eli Gilboa},
  journal={The Journal of Experimental Medicine},
  pages={465 - 472}
Immunization with defined tumor antigens is currently limited to a small number of cancers where candidates for tumor rejection antigens have been identified. In this study we investigated whether pulsing dendritic cells (DC) with tumor-derived RNA is an effective way to induce CTL and tumor immunity. DC pulsed with in vitro synthesized chicken ovalbumin (OVA) RNA were more effective than OVA peptide-pulsed DC in stimulating primary, OVA-specific CTL responses in vitro. DC pulsed with… 

Figures from this paper

Dendritic cells, pulsed with lysate of allogeneic tumor cells, are capable of stimulating MHC-restricted antigen-specific antitumor T cells

Lysate from allogeneic tumor cells may be used as a source of antigens to stimulate tumorspecific T cells in melanoma and potent cytotoxicity against melanoma targets is demonstrated.

Enhancement of Antigen-Presenting Capacity and Antitumor Immunity of Dendritic Cells Pulsed With Autologous Tumor-Derived RNA in Mice

Dendritic cells could sufficiently uptake exogenous tumor-derived RNA, and consequently grow to be an intermediate maturate type, and induce potent T-cell stimulation and fully cause an antitumor effect in vivo.

RNA transfection of dendritic cells.

A polyvalent vaccine might be able to reduce the probability of clonal tumor escape and to elicit CTL responses directed against naturally processed and presented immuno-dominant tumor antigens and has the potential of broad clinical application.

Antigen‐presenting cells pulsed with unfractionated tumor‐derived peptides are potent tumor vaccines

This study suggests that APC loaded with unfractionated peptides derived from poorly immunogenic, highly metastatic tumor cells may represent a potent form of tumor vaccine.

Strategies for antigen loading of dendritic cells to enhance the antitumor immune response.

Correlation of in vitro data with the generation of protective immunity in vivo suggests the utility of irradiated tumor-primed DCs as a means to generate Protective immunity in patients with solid malignancies.

Enhanced therapeutic efficacy of tumor RNA-pulsed dendritic cells after genetic modification with lymphotactin.

The aim is to improve the therapeutic efficacy of DC-based tumor RNA vaccines by augmenting the preferential chemotaxis of DCs to T cells with a new approach to immunological intervention by chemokines.

Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell–based cancer vaccination

The strategy of Ag-loading clearly influences the ability of DCs to polarize T cells for a TH1/TH2 response and thus determines the outcome of the elicited immune response, during various vaccination protocols.

Enhanced dendritic cell antigen presentation in RNA-based immunotherapy.

Efficient mRNA transfection by electroporation as well as dendritic cell maturation results in increased levels of Mart-1/Melan A antigen presentation and enhanced production of antigen-specific effector T cells.

Appropriate Timing of CD40 Ligation for RNA‐Pulsed DCs to Induce Antitumor Immunity

It is demonstrated that DCs pulsed with total RNA extracted from tumor cells required CD40 stimulation with an appropriate sequence to present tumor‐associated antigens, and successfully primed antitumor effector T cells in draining LNs and subsequently induced antitumors protective immunity.

Immunization with Lentiviral Vector-Transduced Dendritic Cells Induces Strong and Long-Lasting T Cell Responses and Therapeutic Immunity 1

Compared with peptide- or protein-pulsed DCs, lentiviral vector-transduced DCs elicit stronger and longer-lasting T cell responses in vivo, as measured by both in vivo killing assays and intracellular production of IFN-γ by Ag-specific T cells.



Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity

It is shown that major histocompatibility complex class I- presented peptide antigen pulsed onto dendritic APCs induces protective immunity to lethal challenge by a tumor transfected with the antigen gene.

Induction of antitumor immunity using bone marrow-generated dendritic cells.

It is shown that a single immunization with DC pulsed with OVA peptide was highly effective in eliciting a protective immune response against a challenge with tumor cells expressing the OVA gene, and that in vivo priming of CTL and induction of antitumor immunity by bone marrow-generated DC also require the presentation of MHC class II-restricted epitopes and activation of CD4+ T cells.

Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes

It is shown that bone marrow-generated DC pulsed with OVA peptide are potent inducers of OVA-specific CTL responses in vivo, compared with splenocytes or RMA-S cells pulsing with Ova peptide, or compared with immunization with free O VA peptide mixed with adjuvant.

Primary stimulation by dendritic cells induces antiviral proliferative and cytotoxic T cell responses in vitro

The results using the hanging drop culture method and DC as APC have implications for studying the T cell repertoire for viral components in humans without the necessity of previous immunization.

Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo

It is shown that mice immunized with syngeneic dendritic cells pulsed in vitro with tumor antigen (BCL1 idiotype expressed by lymphoma cells) are protected against a subsequent tumor inoculation.

Cells treated with TAP-2 antisense oligonucleotides are potent antigen-presenting cells in vitro and in vivo.

TAP-2 AS oligonucleotide-treated adherent splenocytes pulsed with OVA peptide elicited potent OVA-specific CTL responses in vivo and provided effective protection from challenge with tumor cells expressing the corresponding Ag.

Induction of cytotoxic T lymphocytes by primary in vitro stimulation with peptides

In all cases, the antipeptide CTL generated by primary in vitro stimulation were inefficient in lysing target cells expressing endogenous forms of antigens, such as influenza virus-infected cells or cells transfected with the OVA cDNA.

Tumor antigen presentation by murine epidermal cells.

I-A+ epidermal cells are capable of presenting S1509a tumor Ag for the generation of protective antitumor immunity in vivo and to immunize for a significant delayed-type hypersensitivity response to injected tumor cells.

Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor.

The first report demonstrating that mice immunized once i.v. with syngeneic spleen DCs pulsed with the HPV 16 E7(49-57) peptide in vitro were protected against the outgrowth of C3 tumor cells is reported, indicating that spleenDCs pulsing with a CTL epitope can effectively serve as a tumor-specific vaccine.

Soluble proteins delivered to dendritic cells via pH-sensitive liposomes induce primary cytotoxic T lymphocyte responses in vitro

It is demonstrated that a potent primary CTL response against a soluble protein can be achieved by delivering antigen in pH-sensitive liposomes to dendritic cells (DC) either in vivo or in vitro.